Work

Phase II study of novel CXCR2 agonist and Plerixafor for rapid stem cell mobilization in patients with multiple myeloma

Year: 2024

Type: article

Abstract: MGTA-145 or GROβT, a CXCR2 agonist, has shown promising activity for hematopoietic stem cell (HSC) mobilization with plerixafor in pre-clinical studies and healthy volunteers. Twenty-five patients with multiple myeloma enrolled in a phase 2 trial evaluating MGTA-145 and plerixafor for HSC mobilization (NCT04552743). Plerixafor was given subcutaneously followed 2 h later by MGTA-145 (0.03 mg/kg) intravenously with same day apheresis. Mobilization/apheresis could be repeated for a second day in patients who collected <6 ×10 6 CD34+ cells/kg. Lenalidomide and anti-CD38 antibody were part of induction therapy in 92% ( n = 23) and 24% ( n = 6) of patients, respectively. Median total HSC cell yield (CD34+ cells/kg × 10 6 ) was 5.0 (range: 1.1–16.2) and day 1 yield was 3.4 (range: 0.3–16.2). 88% ( n = 22) of patients met the primary endpoint of collecting 2 ×10 6 CD34+ cells/kg in ≤ two days, 68% ( n = 17) in one day. Secondary endpoints of collecting 4 and 6 × 10 6 CD34+ cells/kg in ≤ two days were met in 68% ( n = 17) and 40% ( n = 10) patients. Grade 1 or 2 adverse events (AE) were seen in 60% of patients, the most common AE being grade 1 pain, usually self-limited. All 19 patients who underwent transplant with MGTA-145 and plerixafor mobilized HSCs engrafted successfully, with durable engraftment at day 100. 74% (17 of 23) of grafts with this regimen were minimal residual disease negative by next generation flow cytometry. Graft composition for HSCs and immune cells were similar to a contemporaneous cohort mobilized with G-CSF and plerixafor.

Source: Blood Cancer Journal

DOI: 10.1038/s41408-024-01152-1